PROTEOMICS - Clinical Applications
© WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Editor-in-Chief: Lorna Stimson, Deputy Editor: Lucie Kalvodova
Impact Factor: 2.956
ISI Journal Citation Reports © Ranking: 2014: 26/79 (BIOCHEMICAL RESEARCH METHODS)
Online ISSN: 1862-8354
Associated Title(s): PROTEOMICS
Cover Picture: Proteomics – Clinical Applications 12/2008
In this issue of Proteomics – Clinical Applications you will find the following highlighted articles:
The magic in conditioned medium has been recognized for decades but exactly what it was and how it worked has only begun to come to light more recently. Byproducts of metabolic activity are easy to spot, more challenging are the secreted growth factors and other types of communication molecules. Ogura et al. looked at the litter that surrounded various cancer cells as a potential gold mine. It took only a bit of RP-HPLC and MALDI-TOF panning to turn up nuggets of pro- and pre-proneurotensin/neuromedin N (pre-proNT/NTN), good candidates for small-cell lung cancer biomarkers. Pre-proNT/NTN was found in medium from 4 out of 7 different small-cell lung carcinomas but 0 out of 8 non-small-cell carcinomas.
Ogura, S.-i. et al., Proteomics Clin. Appl. 2008, 2, 1620–1627.
Creating animal models of inherited human diseases is not always a simple issue of replacing an animal gene with the human equivalent. Huntington's Disease (HD), caused at least in part by the development of expanded polyglutamine (CAG)n sequences in the huntingtin gene, has been modeled in mice with n>60 (CAG)n sequences but this leads to expression as a juvenile form of the disease. Nguyen et al. have developed transgenic rats that come much closer to the pattern of adult human HD in the character and time of appearance of motor deficits, cognitive decline, and emotional disturbance. After thorough micro array evaluation of the rat model at ages 3 and 12 months, these researchers argue that they are much closer to a system suitable for selection and application of biomarkers and potential therapeutics.
Nguyen, H. P. et al., Proteomics Clin. Appl. 2008, 2, 1638–1650.
To be able to have your cake and eat it, too, is one of those things economists tell us is impossible. Don't tell Rader et al. though. They are investigating methods to simplify and speed up human papilloma virus (HPV) biomarker screening from the same sample. This would be very useful for cervical cancer staging, still a problem despite the recent introduction and growing use of a vaccine for the most frequent cancer-causing HPV types. Cervical samples were collected into a tube containing an RNA stabilizing reagent, from which proteins could be extracted and freed of cervical mucus. RNA could be extracted from the same samples with Trizol reagent according to the manufacturer's directions. Proteins recovered were cleanly analyzed by 2-D DIGE and Western blots; total RNA could be analyzed on human cDNA arrays.
Rader, J. S. et al., Proteomics Clin. Appl. 2008, 2, 1658–1669.